In conclusion, differential expression of TRAIL-R1, TRAIL-R2 and TRAIL-R4 may help to histopathologically identify hepatocellular carcinoma patients who could benefit from TRAIL-based therapies. This evidence concerns the gene TNFRSF10A and hepatocellular carcinoma.